In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Dasiglucagon | Synthetic analog Semaglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 97 | 4,624 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 43 (43 in people) | 1,224 (1,221 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 21 | 663 · 284 active124 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Zegalogue says: “Severe hypoglycemia in adults and children with diabetes aged 6 years and older”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Dasiglucagon | Semaglutide |
|---|---|---|
| Adverse eventsWhole body | 2323 | 7757723 |
| Glycemic controlMetabolic and weight |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Ozempic says: “Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; reduce the risk of sustained eGFR decline…”
4848
66866512 |
| Gastrointestinal adverse eventsGastrointestinal | 1111 | 345345 |
|---|
| MortalityWhole body | 11 | 1041031 |
|---|
| Appetite and food intakeMetabolic and weight | 11 | 97952 |
|---|
| PharmacokineticsPharmacology | 33 | 93894 |
|---|
| Heart functionCardiovascular | 88 | 67616 |
|---|
| Immune responseImmune and inflammation | 11 | 44 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Dasiglucagon differs from Human glucagon at 7 positions.
What is different
Semaglutide differs from Glucagon-like peptide 1 (7-37) at 2 positions and carries 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Dasiglucagon | Semaglutide |
|---|---|---|
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in % | 7% Time in hypoglycemia · 80 µg dasiglucagon (D80) Dose studied: 80 µgn = 202022 | 32.6% Time in range Dose studied: 2.4 mg32 weeksn = 312023 |
| Gastrointestinal adverse eventsGastrointestinalCompared as: share of people in the arm that got the peptide, in % | 44 to 56% Nausea incidence Dose studied: 0.1, 0.3, 0.6, or 1.0 mgn not reported2018 | 43.9% Nausea incidence · semaglutide 2.4 mg Dose studied: 2.4 mg once weekly68 weeksn = 3,3792022 |
7%
Time in hypoglycemia · 80 µg dasiglucagon (D80)
Dose studied: 80 µgn = 202022
32.6%
Time in range
Dose studied: 2.4 mg32 weeksn = 312023
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Dasiglucagon | Semaglutide |
|---|---|---|
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | 8% Paracetamol AUC0-5h increase Dose studied: 2.4 mg once weekly (dose-escalated)20 weeksn = 72 |
44 to 56%
Nausea incidence
Dose studied: 0.1, 0.3, 0.6, or 1.0 mgn not reported2018
43.9%
Nausea incidence · semaglutide 2.4 mg
Dose studied: 2.4 mg once weekly68 weeksn = 3,3792022
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in h·nmol/l | No comparable result 1 randomized-trial result measure it in another way or another unit. | 233 h·nmol/L AUC0-24h,sema,SS · 3 mg oral semaglutide Dose studied: 3 mg12 weeksn = 322024 |
|---|
| Heart functionCardiovascularCompared as: value in the arm that got the peptide, in % | No comparable result 8 randomized-trial results measure it in another way or another unit. | −17% Loop diuretic dose decrease · Shown as a change. The study reports a loop diuretic dose decrease of this size. Dose studied: 2.4 mg once weekly52 weeksn not reported2024 |
|---|
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | 86.2% Adverse events · semaglutide 0.5 mg Dose studied: 0.5 mg56 weeksn = 6012018 |
|---|
No comparable result
1 randomized-trial result measure it in another way or another unit.
8%
Paracetamol AUC0-5h increase
Dose studied: 2.4 mg once weekly (dose-escalated)20 weeksn = 722021
No comparable result
1 randomized-trial result measure it in another way or another unit.
233 h·nmol/L
AUC0-24h,sema,SS · 3 mg oral semaglutide
Dose studied: 3 mg12 weeksn = 322024
No comparable result
8 randomized-trial results measure it in another way or another unit.
−17%
Loop diuretic dose decrease · Shown as a change. The study reports a loop diuretic dose decrease of this size.
Dose studied: 2.4 mg once weekly52 weeksn not reported2024
No comparable result
2 randomized-trial results measure it in another way or another unit.
86.2%
Adverse events · semaglutide 0.5 mg
Dose studied: 0.5 mg56 weeksn = 6012018
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 21 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Zealand Pharma170 participants7 Dec 2017 to 25 May 2018
Hypoglycemia · Diabetes Mellitus, Type 1
Zealand Pharma112 participants28 Jun 2017 to 13 Feb 2018
Hypoglycemia · Diabetes Mellitus, Type 1
Zealand Pharma45 participants1 Nov 2018 to 11 Mar 2019
Hypoglycemia · Diabetes Mellitus, Type 1
Top 3 of 663 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S17,604 participants24 Oct 2018 to 29 Jun 2023
Overweight · Obesity
Novo Nordisk A/S9,651 participants17 Jun 2019 to 23 Aug 2024
Diabetes Mellitus, Type 2
Novo Nordisk A/S3,533 participants17 Jun 2019 to 9 Jan 2024
Diabetes Mellitus, Type 2
124 more mention it but do not test it. They only measure it or name it in their text.